

ONYX PHARMA - Carfilzomib Approval - Now or Later?

https://marketpublishers.com/r/OA55534EF01EN.html

Date: November 2011

Pages: 3

Price: US\$ 140.00 (Single User License)

ID: OA55534EF01EN

Abstracts

Future growth remains tied to the Approval of Carfilzomib (PhIIb, next-generation proteasome inhibitor, Relapsed and Refractory Multiple Myeloma - R/R MM). Delay could limit the potential of Carfilzomib, as generic Takeda's Velcade (L, MM – first and second-line, MCL) might become available from 2017 coupled with probable approval of Celgene's Pomalidimide (PhII, RR MM). There are two registration PhIII trials underway – ASPIRE (International) and FOCUS (EU), and interim data from these studies are expected to be out only in 1H13. Moreover, Bayer settled its litigation with ONXX... For more details, please read our report, released on Nov. 8, 2011 on "Onyx Pharma - Carfilzomib Approval – Now or Later?"



Contents

COMPANIES MENTIONED

ONYX



I would like to order

Product name: ONYX PHARMA - Carfilzomib Approval - Now or Later?

Product link: https://marketpublishers.com/r/OA55534EF01EN.html

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/OA55534EF01EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970